NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $329.15 +0.60 (+0.18%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$327.91▼$330.9950-Day Range$298.50▼$335.9752-Week Range$248.38▼$346.85Volume1.14 million shsAverage Volume2.59 million shsMarket Capitalization$176.57 billionP/E Ratio47.02Dividend Yield2.73%Price Target$326.89 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amgen alerts: Email Address Amgen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside0.7% Downside$326.89 Price TargetShort InterestBearish1.83% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-2.42Upright™ Environmental ScoreNews Sentiment0.56Based on 18 Articles This WeekInsider TradingN/AProj. Earnings Growth5.69%From $19.50 to $20.61 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector132nd out of 924 stocksBiological Products, Except Diagnostic Industry14th out of 145 stocks 2.3 Analyst's Opinion Consensus RatingAmgen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 11 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageAmgen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.83% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Amgen has recently increased by 2.19%, indicating that investor sentiment is decreasing. Previous Next 3.3 Dividend Strength Dividend YieldAmgen pays a meaningful dividend of 2.77%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 43.67% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.Environmental SustainabilityThe Environmental Impact score for Amgen is -2.42. Previous Next 3.1 News and Social Media Coverage News SentimentAmgen has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Amgen this week, compared to 21 articles on an average week.Search Interest45 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 45% compared to the previous 30 days.MarketBeat Follows32 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 129% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amgen are expected to grow by 5.69% in the coming year, from $19.50 to $20.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 47.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 47.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.77.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.78. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 28.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Amgen Stock (NASDAQ:AMGN)Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More AMGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMGN Stock News HeadlinesAugust 21 at 10:06 PM | marketbeat.comBoogers, Biotech and Health Insurance: The Safest Dividends for a RecessionLet’s talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one.August 10, 2024 | marketbeat.comMarketBeat Week in Review – 8/5 - 8/9 (AMGN)Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earningsAugust 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.August 9, 2024 | marketbeat.comAmgen's MariTide Weight Loss Potential: Stock Outlook (AMGN)Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.August 21 at 11:35 PM | marketwatch.comAmgen Inc. stock rises Wednesday, still underperforms marketAugust 21 at 8:33 AM | msn.comAMGN Bullish Diagonal Trade Targets a Price of $350 by October 18thAugust 20 at 9:00 AM | prnewswire.comOTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASISAugust 18, 2024 | finance.yahoo.comAMGN Aug 2024 357.500 put (AMGN240823P00357500)August 22, 2024 | Colonial Metals (Ad)Wanted Dead: PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.August 18, 2024 | fool.com2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a DecadeAugust 17, 2024 | finance.yahoo.comAMGN Aug 2024 360.000 put (AMGN240823P00360000)August 17, 2024 | fool.comThis Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the PipelineAugust 15, 2024 | marketwatch.comAmgen Inc. stock rises Thursday, still underperforms marketAugust 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Incyte (INCY) and Gilead Sciences (GILD)August 14, 2024 | msn.comAmgen Inc. (AMGN): Pioneering Healthcare Innovations in Obesity TreatmentAugust 14, 2024 | finance.yahoo.comEarnings Troubles May Signal Larger Issues for Amgen (NASDAQ:AMGN) ShareholdersAugust 14, 2024 | americanbankingnews.comAmgen Inc. (AMGN) to Issue Quarterly Dividend of $2.25 on September 6thAugust 14, 2024 | americanbankingnews.comAnalyzing Cabaletta Bio (NASDAQ:CABA) and Amgen (NASDAQ:AMGN)See More Headlines Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 6/7 Dividend5/16/2024Dividend Payable6/07/2024Last Earnings8/06/2024Dividend Payable8/06/2024Ex-Dividend for 8/6 Dividend8/16/2024Today8/21/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees25,200Year Founded1980Price Target and Rating Average Stock Price Target$326.89 High Stock Price Target$381.00 Low Stock Price Target$235.00 Potential Upside/Downside-0.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)$7.00 Trailing P/E Ratio47.02 Forward P/E Ratio16.88 P/E Growth2.78Net Income$6.72 billion Net Margins12.74% Pretax Margin14.71% Return on Equity156.21% Return on Assets10.82% Debt Debt-to-Equity Ratio11.96 Current Ratio1.42 Quick Ratio0.98 Sales & Book Value Annual Sales$30.93 billion Price / Sales5.71 Cash Flow$25.86 per share Price / Cash Flow12.73 Book Value$11.65 per share Price / Book28.25Miscellaneous Outstanding Shares536,435,000Free Float532,734,000Market Cap$176.57 billion OptionableOptionable Beta0.58 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Robert A. Bradway (Age 61)Chairman, CEO & President Comp: $6.73MMr. Peter H. Griffith (Age 65)Executive VP & CFO Comp: $3.07MMr. Esteban Santos (Age 56)Executive Vice President of Operations Comp: $3.01MDr. David M. Reese M.D. (Age 61)Executive VP & Chief Technology Officer Comp: $3.4MMr. Murdo Gordon (Age 57)Executive Vice President of Global Commercial Operations Comp: $3.24MMr. Matthew C. Busch (Age 50)Chief Accounting Officer & VP of Finance Mr. Mike ZahigianSenior VP & Chief Information OfficerDr. James E. Bradner M.D. (Age 52)Executive VP of Research and Development & Chief Scientific Officer Justin G. ClaeysVice President of Investor RelationsMr. Jonathan P. Graham (Age 63)Executive VP, General Counsel & Secretary Comp: $2.44MMore ExecutivesKey CompetitorsRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXGilead SciencesNASDAQ:GILDSeagenNASDAQ:SGENAlnylam PharmaceuticalsNASDAQ:ALNYView All CompetitorsInsiders & InstitutionsGranite Bay Wealth Management LLCBought 748,200 shares on 8/21/2024Ownership: 0.141%Truist Financial CorpBought 51,795 shares on 8/21/2024Ownership: 0.128%IMS Capital ManagementSold 599 shares on 8/21/2024Ownership: 0.001%SPC Financial Inc.Bought 162 shares on 8/21/2024Ownership: 0.000%Pathway Financial Advisers LLCBought 257 shares on 8/20/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions Should I Buy Amgen Stock? AMGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Amgen Inc.: Amgen's stock price has shown resilience, trading at $312.50 on August 19, 2024. Amgen has a diverse portfolio of successful products, including Enbrel, Otezla, and Repatha, catering to various medical needs. Recent analyst reports have raised price targets for Amgen, indicating positive sentiment and potential growth. Amgen's consistent dividend payments provide investors with a steady income stream. Amgen's strong market capitalization of $167.64 billion reflects its stability and market presence. Cons Investors should be bearish about investing in Amgen Inc. for these reasons: Amgen's dividend payout ratio is currently high at 128.57%, indicating a significant portion of earnings being distributed as dividends. Amgen's price-to-earnings ratio of 44.64 may suggest the stock is relatively expensive compared to industry peers. Amgen's debt-to-equity ratio of 11.96 is relatively high, which could pose risks in times of economic downturns. While Amgen has a strong product pipeline, competition in the biotech industry is intense, leading to potential market share challenges. The stock's 52-week high of $346.85 may indicate limited short-term upside potential based on historical performance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com. AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $288.02 at the beginning of the year. Since then, AMGN shares have increased by 14.3% and is now trading at $329.15. View the best growth stocks for 2024 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its earnings results on Tuesday, August, 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts' consensus estimates of $5.01 by $0.04. The firm's revenue for the quarter was up 20.1% on a year-over-year basis. Read the conference call transcript. What is Robert A. Bradway's approval rating as Amgen's CEO? 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend. Does Amgen have any subsidiaries? Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Amgen's top institutional investors include Primecap Management Co. CA (2.69%), Bank of New York Mellon Corp (1.00%), Legal & General Group Plc (0.90%) and Dimensional Fund Advisors LP (0.50%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV) and Walt Disney (DIS). This page (NASDAQ:AMGN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
